June 23, 2016
Wellesley, Mass., June 23, 2016 –The global cardiac biomarker market should see excellent growth rates among major regions due to the growing prevalence and incidence rates of cardiac diseases. BCC Research reveals in its new report that the Asia-Pacific (APAC) region, in particular, should see a substantial growth rate percentage well into the teens.
The global market for in vitro diagnostic tests for cardiac biomarkers is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020 from $4.9 billion in 2015. As a segment, APAC should move the fastest at a five-year CAGR of 17.6%. Because of the ever-expanding medical infrastructure and services in this region, APAC should surpass Europe as the second-largest segment by 2020. Meanwhile, the U.S. market will demonstrate the only single digit growth rate among all regions, a five-year CAGR of 9.5%.
This report investigates one of the most important drivers in the in vitro diagnostics market: the introduction of additional biomarkers for heart failure, including ST2, galectin-3 and others, as well as ongoing research of biomarkers for stroke such as GFAP and S100-beta. Together, they are expected to substantially contribute to the growth of the market for cardiac biomarkers over the forecast period of 2015-2020.
Both cTnI and natriuretic peptide assays led the market by a wide margin in 2014. However, they should see modest growth with five-year CAGRs of 7.3% and 10.5%, respectively. Troponin is considered as the gold standard of the biomarker assays while proBNP and proANP are the top natriuretic peptides.
Meanwhile, novel CHF biomarkers, namely, galectin-3, ST2 and copeptin, and the approval of a stroke biomarker in 2015, are expected to grow the market with five-year CAGRs of 14% and 23%, respectively. In contrast, well-established biomarkers like CK-MB are trending downward. Once regarded as the top biomarker, CK-MB is projected to decline at a five-year CAGR of -5% from 2015 to 2020.
Troponins and natriuretic peptides offer results with great analytical sensitivity. As such, these biomarkers are providing researchers and medical practitioners with a novel tool that helps them to eliminate irrelevant syndromes in cardiac diseases and also provide low analytical imprecision at low ranges.
A key industry trend is China’s emergence as the leading force in the Asian drug discovery market. This growth is attributed to Chinese firms accepting projects from international clients, the rapid expansion of CRO’s in China, and more companies in the U.S. and Europe outsourcing their services to China.
“There have been constant rise in the biotechnology start-ups in the Chinese region. According to an estimate the ‘Drug Valley’ in China is home to 250 pharmaceuticals companies, out of which 60% are CRO or service providers,” says BCC Research analyst Anuj Pathak. “The Asia-Pacific market, which is expected to increase at a five-year CAGR at 17.6% during the forecast period, should surpass the European market to become the second-largest cardiac biomarker market (behind the U.S.) by 2020.”
Cardiac Biomarkers: Technologies and Global Markets (BIO128B) analyzes the industry structure, including key markets, major companies and their market shares. Analyses of global market drivers and trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
Cardiac Biomarkers: Technologies and Global Markets( BIO128B )
Publish Date: Jun 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.